The six-year-old Eliquis (Apixaban) substance patent lawsuit will be closed next week in the Supreme Court. If the Supreme Court overturns the judgment of the first and second trials and takes the side of the original company, BMS, an all-round lawsuit for damages against related generic companies is expected and attracts attention.

The ruling is expected to affect Eliquis prices. It has not yet been lowered even after the generic launch, because BMS has filed a court request to suspend the drug price reduction until the final conclusion of substance patent lawsuit for Eliquis is concluded.

According to the pharmaceutical industry on the 2nd, the Supreme Court announced on the 8th the da